{"ticker": {"uuid": "2d47c724-e4c5-4645-ba55-da1de07223c5", "symbol": "DRUG", "name": "Bright Minds Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5% - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQNlhMSXFEZmJmOEZ0d3I4N19hOUJuZ1dqOHNyVVRyRG0wb1JTbHZITXNYNWhYOVI4Z3N5ZDdPaGNCd3NMZm9fTEc1Wk9MZjVtbWtGd1doaVJFOHhMR3pwZTJlYWJTbkszNTRhbWtKbW9UQnRlcnktVTZOaVNFaGgyY1RpQ0xsQ1R2dThUS2dVZjY3dW1BeGkyNnJ5RUlEYWp3OVpycmhsUGhUV0FTQkxvUnktcDU4WlE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T17:17:59+00:00", "published_display": "17 Jul 2026 17:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Understanding Momentum Shifts in (DRUG)", "summary": "This article analyzes Bright Minds Biosciences Inc. (DRUG) using AI models to identify momentum shifts and provide trading strategies. Key findings indicate strong sentiment across all horizons, an 87.9:1 risk-reward setup, and several actionable trading strategies for different ", "url": "https://news.stocktradersdaily.com/news_release/1/Understanding_Momentum_Shifts_in_DRUG_071326061001_1783937401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T06:11:41", "published_display": "13 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake", "summary": "Bright Minds Biosciences Inc. CEO, Ian McDonald, has reported a 13.6% beneficial ownership stake in the company, amounting to 1,398,290 common shares as of July 2, 2026. This updated figure reflects his sole voting and dispositive power, with previous filings showing varying perc", "url": "https://www.stocktitan.net/sec-filings/DRUG/schedule-13d-a-bright-minds-biosciences-inc-amended-major-shareholder-1d7f01698b62.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:17", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com", "summary": "This article announces that BRIGHT MINDS BIOSCIENCES INC. filed a Form 13D/A on July 2nd. The content of the filing itself is not provided, but the article focuses on this specific regulatory event. It is a brief news item indicating a recent corporate action.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-bright-minds-biosciences-inc-for-2-july-93CH-4719210", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:40:17", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (DRUG) Movement", "summary": "This article provides a real-time analysis of Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting strong sentiment across all horizons and a current breakdown in price. It presents specific institutional trading strategies, including position trading, momentum breakout, an", "url": "https://news.stocktradersdaily.com/news_release/9/Avoiding_Lag:_Real-Time_Signals_in_DRUG_Movement_070226050201_1782982921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T04:39:04", "published_display": "02 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxNakFsNmp4SkRVcGI1Y2JFYTJxRmg0V3VWRWoxVjdrTTdTM3hzUVZDeXRlSFJNNFJGaDFkamlCRVIzNDFIUUdLbmtORXZoQUptRm1rWEQ0Z3ppVXczN0lBVDk0aC1FM3p6SElwZzVxVjdUTHlra1F5azNITEtGSUM5eVJpdUU2MnkxTXlfOU1hVjdYdW80Wk16Q183dEJVdEw5WXMtY1pzODg4R082R2xaM3d2QzFYMVQxdXpKWkhfRzk5N3gtaXRjQTdZVWY1M1Z1aUhCbjZyU0pjdGNLZi1XaTRFNjB2UzdnQW1NX0l3d1ZPZTA20gH6AUFVX3lxTE43eFBqTjJnRkxVbzNpRkJBdmZXTVJzSXBCSmRFQTc4Sk4xXzZjeURaNVpGR3FOX1RWLUxiZWtuSHgtWjBRY0dET0h6RS1RZHlta2taeFFnbTlQemIxbS1CSFViY29iNDlFTnk3WlFoVWxRZ1N6cFF4bEFnb2V2Vy1lcFlYcHRhLU1tY0N4dXJ6eTBrV3FtNHlINnZnWE5ZSDRZY2xBQnp1NklJVlpUUEtobmtQMGxBWlMweXp6S3RtNWpzR1JjWjh6RUJQaGZRbmJpYzRJam9Ld0FWTy10VlVGQmxkMm5CYWVPTmF2SmltZnlXYjhRYUQ3U0E?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Bright Minds Biosciences Inc. (DRUG) stock for 2027, based on analyst opinions. It details the current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also answer", "url": "https://www.tradingview.com/symbols/CSE-DRUG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:41:36", "published_display": "27 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG)", "summary": "This article provides key financial data and analyst estimates for Bright Minds Biosciences Inc. (CSE:DRUG). It details the company's stock performance, market capitalization, earnings, and revenue, alongside analyst price targets and volatility metrics. The information is presen", "url": "https://www.tradingview.com/symbols/CSE-DRUG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:53", "published_display": "27 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides financial insights into Bright Minds Biosciences Inc. (DRUG), detailing its revenue streams, profitability margins, and a comparison with competitors like EPRX and PRME. While specific gross, operating, and net margins for DRUG are listed as N/A, its Return ", "url": "https://intellectia.ai/en/stock/DRUG/financials", "source_name": "Intellectia AI", "published_at": "2026-06-22T07:11:26", "published_display": "22 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Bright Minds Biosciences Inc (DRUG). It aggregates 11 technical signals, indicating a \"Neutral\" overall sentiment with 5 buy and 6 sell indicators. The analysis covers momentum indicators like RSI and MACD, s", "url": "https://intellectia.ai/en/stock/DRUG/technical", "source_name": "Intellectia AI", "published_at": "2026-06-21T20:12:15", "published_display": "21 Jun 2026 20:12", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in DRUG Response", "summary": "This article provides an AI-generated analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies including position, momentum breakout, and risk hedging, alo", "url": "https://news.stocktradersdaily.com/news_release/10/Discipline_and_Rules-Based_Execution_in_DRUG_Response_062126035002_1782028202.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T03:50:00", "published_display": "21 Jun 2026 03:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Bright Minds Biosciences Inc's (DRUG) institutional confidence score, which is currently 0.00. It details the shareholdings of key institutional investors, including Janus Henderson Investors, McDonald (Ian), and Cormorant Asse", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:10", "published_display": "18 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bright Minds Biosciences Inc (DRUG) earnings forecast indicates a \"Buy\" trend based on 7 analysts, with a target price of USD 148.557, suggesting a 148.34% upside. The company's recent EPS was USD -0.71, exceeding the market expectation of USD -0.78, and the next quarter's EPS is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:21", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Bright Minds Biosciences Inc (DRUG), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The overview also includes the current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:21", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc", "summary": "This article provides a revenue breakdown for Bright Minds Biosciences Inc (DRUG), indicating that relevant financial data has not yet been disclosed by the company, either by business segment or by region. It also includes current stock information, showing a slight decrease in ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:10:13", "published_display": "18 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Bright Minds Biosciences Inc (DRUG), providing lists of major shareholders by proportion and institutional holdings over several quarters. It also categorizes shareholders by type and lists the company's proportion in various rela", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:13", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of DRUG and Institutional Flows", "summary": "This article from Stock Traders Daily analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/1/Behavioral_Patterns_of_DRUG_and_Institutional_Flows_061026024201_1781073721.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-10T02:10:20", "published_display": "10 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "News Releases for Bright Minds Biosciences Inc.", "summary": "This page provides news releases for Bright Minds Biosciences Inc., a company listed on the Canadian Securities Exchange (CSE) under the symbol DRUG. It includes information on the company's status, industry, issued and outstanding shares, and links to various filings and news up", "url": "https://www.thecse.com/listings/bright-minds-biosciences-inc/news-releases/?page=8", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2026-06-06T19:39:32", "published_display": "06 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG - Bright Minds Biosciences Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Bright Minds Biosciences Inc. (DRUG), including its stock price, market cap, key financial ratios, and recent news events. It details analyst ratings, insider transactions, and upcoming conference presentations, offe", "url": "https://finviz.com/stock?t=DRUG", "source_name": "Finviz", "published_at": "2026-06-05T12:40:01", "published_display": "05 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145", "summary": "H.C. Wainwright has reiterated its Buy rating for Bright Minds Biosciences (DRUG.US) and maintained a target price of $145. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70932294/hc-wainwright-maintains-bright-minds-biosciences-drugus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-03T00:39:32", "published_display": "03 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates", "summary": "Bright Minds Biosciences Inc. (DRUG) has announced the details for its 2026 Annual General Meeting (AGM) to be held in Vancouver on March 31, 2026. The record date for notice, voting, and beneficial ownership determination is set for February 10, 2026. The company will utilize a ", "url": "https://www.stocktitan.net/sec-filings/DRUG/6-k-bright-minds-biosciences-inc-current-report-foreign-issuer-045ff19c8b42.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:40:48", "published_display": "02 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com", "summary": "H.C. Wainwright has reaffirmed its Buy rating and $145 price target for Bright Minds Biosciences (NASDAQ:DRUG) following positive Phase 2 clinical trial results for its drug BMB-101 in treating drug-resistant epilepsy. The stock has seen a significant increase over the past year,", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-bright-minds-stock-rating-on-epilepsy-data-93CH-2539774", "source_name": "Investing.com Nigeria", "published_at": "2026-06-02T11:40:48", "published_display": "02 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeHhXcy1tbF9rYUFBQW9YblBSZzNNdlNSejJGZ042LWZQNDlXMjZJbVRvNUl3a3FZVkJyMWlGT1hTdFBvb0VXSndDNWhjQU02Q2o3ZEpOTDgyUDNncVFZVHdEUVNxS0dJSmllTGpjcDUzTVE1LXp0aTVKWERWMTF2N0FyNTRnYzU5eHFaVXBpVGMzS3BTYkV5R3F4UGVGQmNEY3RvMy1ydGVKZWEyVGZEc0xHWmhKNlE2TGJ6bWQ2M0FTcGpFeHc?oc=5", "source_name": "TipRanks", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options", "summary": "Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight its CNS-focused drug pipeline. The company also granted 109,000 stock options to directors, officers, and consultants, aligning their interests with long", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DRUG/pressreleases/2196295/bright-minds-biosciences-to-present-at-jefferies-healthcare-conference-and-grants-new-stock-options/", "source_name": "The Globe and Mail", "published_at": "2026-06-01T19:10:31", "published_display": "01 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DRUG) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an in-depth algorithmic analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting a strong near-term sentiment shifting to a long-term positive bias. It presents several AI-generated trading strategies including position trading, momentum break", "url": "https://news.stocktradersdaily.com/news_release/1/DRUG_Movement_Within_Algorithmic_Entry_Frameworks_053026011201_1780117921.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T21:39:10", "published_display": "30 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference", "summary": "Bright Minds Biosciences will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT. The company also announced the grant of stock options for 109,000 common shares to directors, officers, and consultants, exercisable at US$83.40 per sha", "url": "https://www.globenewswire.com/news-release/2026/05/26/3301576/0/en/bright-minds-biosciences-to-present-at-jefferies-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T21:09:27", "published_display": "27 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk", "summary": "Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. EDT, with a webcast available for 30 days. The company also granted 109,000 stock options to directors, officers, and consultants. These options are exer", "url": "https://www.stocktitan.net/sec-filings/DRUG/6-k-bright-minds-biosciences-inc-current-report-foreign-issuer-92622a8e8917.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:10:11", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event", "summary": "Bright Minds Biosciences (NASDAQ: DRUG) is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 PM EDT, with a webcast available. The company also announced it granted 109,000 stock options to directors, officers, and consultants at an exerc", "url": "https://www.stocktitan.net/news/DRUG/bright-minds-biosciences-to-present-at-jefferies-global-healthcare-k4fu9bjz3ral.html", "source_name": "Stock Titan", "published_at": "2026-05-26T23:40:16", "published_display": "26 May 2026 23:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220", "summary": "Piper Sandler has reiterated its Buy rating for Bright Minds Biosciences (DRUG.US) and increased its target price to $220. This indicates a positive outlook from the analyst firm regarding the company's future stock performance and value.", "url": "https://www.moomoo.com/news/post/70313968/piper-sandler-maintains-bright-minds-biosciences-drugus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-05-20T19:09:40", "published_display": "20 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler raises Bright Minds stock price target on program progress", "summary": "Piper Sandler has increased its price target for Bright Minds Biosciences (NASDAQ:DRUG) to $220 from $190, maintaining an Overweight rating, due to the company's progress across its programs, including the recruitment for its Phase 2a NOVA study and regulatory discussions for BMB", "url": "https://m.investing.com/news/analyst-ratings/piper-sandler-raises-bright-minds-stock-price-target-on-program-progress-93CH-4701101?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-20T12:10:01", "published_display": "20 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 89, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bright Minds Biosciences Announces Closing of US$175 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPZEpMOGdkTnJ0UXd3dHFQSE05TUFYWGZfSkhOZ0c4Mk9sZzBPUFlSdDBVOXN3ZWRMU2tCSzNmQzlCUFRLSUF0YndmdGFkQ19MVmNhMV9pNlFjaXU0M2RCYm1CVS1NWDhpTUF2RlJsRk10aWZUX2QxcHhENlpXN3cyX2RhSXhPcHNkWnZxY0FETWhIUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bright Minds Biosciences Stock Topped the Market on Monday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVFJUTlN5SzJtcGpVeXNVNmpHMGs3cG9vNV82ZHBSbkozaV9rVzN0RkFwS0xadDdNTThhVDZBY0s2dm9QQzhtYm5GQUVQajFVcHByUnRETVVJdFdoc0lUaVZzY2dTTi1kalM3X1VKeDlxTG41dk96LS1fMkVpNjNjMVd2UmI0RFdHX3hiZGVKOGpFV3BsWjN0Zg?oc=5", "source_name": "The Motley Fool", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (DRUG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA2dDJST2kycG12cHJxYkpJODB3Nl9OR2JwQ0ZWSXdRczZhLXR2SUFLMXhtc21HTVl3aVNta0VWZU10dkF4VmVfaG9aZmRELThwTmp3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T06:03:59+00:00", "published_display": "25 Apr 2025 06:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Stock Surges Almost 1,500%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOT3hmV2ZCelc2RWVFS2pUbEFIMFdRWmV6UlpVZG5zdC1BN1NObGd0LV9uRFNNZzFLSU9odF9iNklhUTAxbl9LcHRiU1RVWEtWSG5XNWR2ZzVjZ0RodVdrd0FXQ3VzM1FaOTdWRzlLNVVIa1poeFNBVExSRGYwX0UyTmN1Ulh1UjlkVGpfaFJ3ZWdzbkhUYmgxeg?oc=5", "source_name": "entrepreneur.com", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $DRUG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9NbDh3SURFdUNuNlhOMlhnNzlkTGNjWjQ5bU80eVBkcTZlMDByMXR4RUR4cWFGZHFYT1Z5UkxobHJ1LXlnZDk1ei1EOUNueGc1eWViaUp2bVNRUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-11-18T11:07:25+00:00", "published_display": "18 Nov 2021 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPSmoyaHNISzlsNkl4WGxvRGJWd25LSUlROHdkaXZYenpDZHdRTXdPOHk5bC1IbjdLam5rRDR1c05xZ01KcFFOTmhBczRGM1NnbHg4V0VXTmd5QkRNZV9UblpHNXJCeXBaVnRQVnpnRzdlaXJ2cXQxcXgzUUQ5UUp2YzBlRlE1QWJRY1JqYTF4NVA0TU9KQ2RXa2xRWnpGYUJzYmtsRXAwSWh3bnhsSlNnMU92b2VaX1ZkSFpReVJCTm9RQkZHR0lHTWhCam1FbDdTeVlSVFVTMHA1Z3dr?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-03-17T07:00:00+00:00", "published_display": "17 Mar 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5% - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQNlhMSXFEZmJmOEZ0d3I4N19hOUJuZ1dqOHNyVVRyRG0wb1JTbHZITXNYNWhYOVI4Z3N5ZDdPaGNCd3NMZm9fTEc1Wk9MZjVtbWtGd1doaVJFOHhMR3pwZTJlYWJTbkszNTRhbWtKbW9UQnRlcnktVTZOaVNFaGgyY1RpQ0xsQ1R2dThUS2dVZjY3dW1BeGkyNnJ5RUlEYWp3OVpycmhsUGhUV0FTQkxvUnktcDU4WlE?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T17:17:59+00:00", "published_display": "17 Jul 2026 17:17", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (DRUG)", "summary": "This article analyzes Bright Minds Biosciences Inc. (DRUG) using AI models to identify momentum shifts and provide trading strategies. Key findings indicate strong sentiment across all horizons, an 87.9:1 risk-reward setup, and several actionable trading strategies for different ", "url": "https://news.stocktradersdaily.com/news_release/1/Understanding_Momentum_Shifts_in_DRUG_071326061001_1783937401.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T06:11:41", "published_display": "13 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake", "summary": "Bright Minds Biosciences Inc. CEO, Ian McDonald, has reported a 13.6% beneficial ownership stake in the company, amounting to 1,398,290 common shares as of July 2, 2026. This updated figure reflects his sole voting and dispositive power, with previous filings showing varying perc", "url": "https://www.stocktitan.net/sec-filings/DRUG/schedule-13d-a-bright-minds-biosciences-inc-amended-major-shareholder-1d7f01698b62.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:40:17", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com", "summary": "This article announces that BRIGHT MINDS BIOSCIENCES INC. filed a Form 13D/A on July 2nd. The content of the filing itself is not provided, but the article focuses on this specific regulatory event. It is a brief news item indicating a recent corporate action.", "url": "https://ca.investing.com/news/stock-market-news/form-13da-bright-minds-biosciences-inc-for-2-july-93CH-4719210", "source_name": "Investing.com Canada", "published_at": "2026-07-02T21:40:17", "published_display": "02 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (DRUG) Movement", "summary": "This article provides a real-time analysis of Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting strong sentiment across all horizons and a current breakdown in price. It presents specific institutional trading strategies, including position trading, momentum breakout, an", "url": "https://news.stocktradersdaily.com/news_release/9/Avoiding_Lag:_Real-Time_Signals_in_DRUG_Movement_070226050201_1782982921.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T04:39:04", "published_display": "02 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Bright Minds Biosciences Inc. (DRUG) stock for 2027, based on analyst opinions. It details the current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also answer", "url": "https://www.tradingview.com/symbols/CSE-DRUG/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T13:41:36", "published_display": "27 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG)", "summary": "This article provides key financial data and analyst estimates for Bright Minds Biosciences Inc. (CSE:DRUG). It details the company's stock performance, market capitalization, earnings, and revenue, alongside analyst price targets and volatility metrics. The information is presen", "url": "https://www.tradingview.com/symbols/CSE-DRUG/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T10:39:53", "published_display": "27 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides financial insights into Bright Minds Biosciences Inc. (DRUG), detailing its revenue streams, profitability margins, and a comparison with competitors like EPRX and PRME. While specific gross, operating, and net margins for DRUG are listed as N/A, its Return ", "url": "https://intellectia.ai/en/stock/DRUG/financials", "source_name": "Intellectia AI", "published_at": "2026-06-22T07:11:26", "published_display": "22 Jun 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Bright Minds Biosciences Inc (DRUG). It aggregates 11 technical signals, indicating a \"Neutral\" overall sentiment with 5 buy and 6 sell indicators. The analysis covers momentum indicators like RSI and MACD, s", "url": "https://intellectia.ai/en/stock/DRUG/technical", "source_name": "Intellectia AI", "published_at": "2026-06-21T20:12:15", "published_display": "21 Jun 2026 20:12", "sentiment": "negative", "sentiment_pct": 37, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in DRUG Response", "summary": "This article provides an AI-generated analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents institutional trading strategies including position, momentum breakout, and risk hedging, alo", "url": "https://news.stocktradersdaily.com/news_release/10/Discipline_and_Rules-Based_Execution_in_DRUG_Response_062126035002_1782028202.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T03:50:00", "published_display": "21 Jun 2026 03:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Bright Minds Biosciences Inc's (DRUG) institutional confidence score, which is currently 0.00. It details the shareholdings of key institutional investors, including Janus Henderson Investors, McDonald (Ian), and Cormorant Asse", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T12:40:10", "published_display": "18 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bright Minds Biosciences Inc (DRUG) earnings forecast indicates a \"Buy\" trend based on 7 analysts, with a target price of USD 148.557, suggesting a 148.34% upside. The company's recent EPS was USD -0.71, exceeding the market expectation of USD -0.78, and the next quarter's EPS is", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:21", "published_display": "18 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Bright Minds Biosciences Inc (DRUG), focusing on key metrics like P/E, P/B, P/S, and P/CF. It notes that relevant data for these valuation ratios have not yet been disclosed by the company. The overview also includes the current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T12:39:21", "published_display": "18 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc", "summary": "This article provides a revenue breakdown for Bright Minds Biosciences Inc (DRUG), indicating that relevant financial data has not yet been disclosed by the company, either by business segment or by region. It also includes current stock information, showing a slight decrease in ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T00:10:13", "published_display": "18 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Bright Minds Biosciences Inc (DRUG), providing lists of major shareholders by proportion and institutional holdings over several quarters. It also categorizes shareholders by type and lists the company's proportion in various rela", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-drug/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T23:10:13", "published_display": "17 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Behavioral Patterns of DRUG and Institutional Flows", "summary": "This article from Stock Traders Daily analyzes Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting weak near and mid-term sentiment but a strong long-term outlook. It provides specific AI-generated trading strategies including position, momentum breakout, and risk hedging,", "url": "https://news.stocktradersdaily.com/news_release/1/Behavioral_Patterns_of_DRUG_and_Institutional_Flows_061026024201_1781073721.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-10T02:10:20", "published_display": "10 Jun 2026 02:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "News Releases for Bright Minds Biosciences Inc.", "summary": "This page provides news releases for Bright Minds Biosciences Inc., a company listed on the Canadian Securities Exchange (CSE) under the symbol DRUG. It includes information on the company's status, industry, issued and outstanding shares, and links to various filings and news up", "url": "https://www.thecse.com/listings/bright-minds-biosciences-inc/news-releases/?page=8", "source_name": "The Canadian Securities Exchange (CSE)", "published_at": "2026-06-06T19:39:32", "published_display": "06 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DRUG - Bright Minds Biosciences Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data and news for Bright Minds Biosciences Inc. (DRUG), including its stock price, market cap, key financial ratios, and recent news events. It details analyst ratings, insider transactions, and upcoming conference presentations, offe", "url": "https://finviz.com/stock?t=DRUG", "source_name": "Finviz", "published_at": "2026-06-05T12:40:01", "published_display": "05 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145", "summary": "H.C. Wainwright has reiterated its Buy rating for Bright Minds Biosciences (DRUG.US) and maintained a target price of $145. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70932294/hc-wainwright-maintains-bright-minds-biosciences-drugus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-03T00:39:32", "published_display": "03 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates", "summary": "Bright Minds Biosciences Inc. (DRUG) has announced the details for its 2026 Annual General Meeting (AGM) to be held in Vancouver on March 31, 2026. The record date for notice, voting, and beneficial ownership determination is set for February 10, 2026. The company will utilize a ", "url": "https://www.stocktitan.net/sec-filings/DRUG/6-k-bright-minds-biosciences-inc-current-report-foreign-issuer-045ff19c8b42.html", "source_name": "Stock Titan", "published_at": "2026-06-02T15:40:48", "published_display": "02 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com", "summary": "H.C. Wainwright has reaffirmed its Buy rating and $145 price target for Bright Minds Biosciences (NASDAQ:DRUG) following positive Phase 2 clinical trial results for its drug BMB-101 in treating drug-resistant epilepsy. The stock has seen a significant increase over the past year,", "url": "https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-bright-minds-stock-rating-on-epilepsy-data-93CH-2539774", "source_name": "Investing.com Nigeria", "published_at": "2026-06-02T11:40:48", "published_display": "02 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeHhXcy1tbF9rYUFBQW9YblBSZzNNdlNSejJGZ042LWZQNDlXMjZJbVRvNUl3a3FZVkJyMWlGT1hTdFBvb0VXSndDNWhjQU02Q2o3ZEpOTDgyUDNncVFZVHdEUVNxS0dJSmllTGpjcDUzTVE1LXp0aTVKWERWMTF2N0FyNTRnYzU5eHFaVXBpVGMzS3BTYkV5R3F4UGVGQmNEY3RvMy1ydGVKZWEyVGZEc0xHWmhKNlE2TGJ6bWQ2M0FTcGpFeHc?oc=5", "source_name": "TipRanks", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options", "summary": "Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, to highlight its CNS-focused drug pipeline. The company also granted 109,000 stock options to directors, officers, and consultants, aligning their interests with long", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DRUG/pressreleases/2196295/bright-minds-biosciences-to-present-at-jefferies-healthcare-conference-and-grants-new-stock-options/", "source_name": "The Globe and Mail", "published_at": "2026-06-01T19:10:31", "published_display": "01 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(DRUG) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an in-depth algorithmic analysis for Bright Minds Biosciences Inc. (NASDAQ: DRUG), highlighting a strong near-term sentiment shifting to a long-term positive bias. It presents several AI-generated trading strategies including position trading, momentum break", "url": "https://news.stocktradersdaily.com/news_release/1/DRUG_Movement_Within_Algorithmic_Entry_Frameworks_053026011201_1780117921.html", "source_name": "Stock Traders Daily", "published_at": "2026-05-30T21:39:10", "published_display": "30 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference", "summary": "Bright Minds Biosciences will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT. The company also announced the grant of stock options for 109,000 common shares to directors, officers, and consultants, exercisable at US$83.40 per sha", "url": "https://www.globenewswire.com/news-release/2026/05/26/3301576/0/en/bright-minds-biosciences-to-present-at-jefferies-global-healthcare-conference.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T21:09:27", "published_display": "27 May 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk", "summary": "Bright Minds Biosciences announced it will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 p.m. EDT, with a webcast available for 30 days. The company also granted 109,000 stock options to directors, officers, and consultants. These options are exer", "url": "https://www.stocktitan.net/sec-filings/DRUG/6-k-bright-minds-biosciences-inc-current-report-foreign-issuer-92622a8e8917.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:10:11", "published_display": "27 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event", "summary": "Bright Minds Biosciences (NASDAQ: DRUG) is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2026, at 4:20 PM EDT, with a webcast available. The company also announced it granted 109,000 stock options to directors, officers, and consultants at an exerc", "url": "https://www.stocktitan.net/news/DRUG/bright-minds-biosciences-to-present-at-jefferies-global-healthcare-k4fu9bjz3ral.html", "source_name": "Stock Titan", "published_at": "2026-05-26T23:40:16", "published_display": "26 May 2026 23:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220", "summary": "Piper Sandler has reiterated its Buy rating for Bright Minds Biosciences (DRUG.US) and increased its target price to $220. This indicates a positive outlook from the analyst firm regarding the company's future stock performance and value.", "url": "https://www.moomoo.com/news/post/70313968/piper-sandler-maintains-bright-minds-biosciences-drugus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-05-20T19:09:40", "published_display": "20 May 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler raises Bright Minds stock price target on program progress", "summary": "Piper Sandler has increased its price target for Bright Minds Biosciences (NASDAQ:DRUG) to $220 from $190, maintaining an Overweight rating, due to the company's progress across its programs, including the recruitment for its Phase 2a NOVA study and regulatory discussions for BMB", "url": "https://m.investing.com/news/analyst-ratings/piper-sandler-raises-bright-minds-stock-price-target-on-program-progress-93CH-4701101?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-20T12:10:01", "published_display": "20 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 89, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Announces Closing of US$175 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPZEpMOGdkTnJ0UXd3dHFQSE05TUFYWGZfSkhOZ0c4Mk9sZzBPUFlSdDBVOXN3ZWRMU2tCSzNmQzlCUFRLSUF0YndmdGFkQ19MVmNhMV9pNlFjaXU0M2RCYm1CVS1NWDhpTUF2RlJsRk10aWZUX2QxcHhENlpXN3cyX2RhSXhPcHNkWnZxY0FETWhIUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Bright Minds Biosciences Stock Topped the Market on Monday", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVFJUTlN5SzJtcGpVeXNVNmpHMGs3cG9vNV82ZHBSbkozaV9rVzN0RkFwS0xadDdNTThhVDZBY0s2dm9QQzhtYm5GQUVQajFVcHByUnRETVVJdFdoc0lUaVZzY2dTTi1kalM3X1VKeDlxTG41dk96LS1fMkVpNjNjMVd2UmI0RFdHX3hiZGVKOGpFV3BsWjN0Zg?oc=5", "source_name": "The Motley Fool", "published_at": "2025-11-17T08:00:00+00:00", "published_display": "17 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (DRUG) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFA2dDJST2kycG12cHJxYkpJODB3Nl9OR2JwQ0ZWSXdRczZhLXR2SUFLMXhtc21HTVl3aVNta0VWZU10dkF4VmVfaG9aZmRELThwTmp3?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T06:03:59+00:00", "published_display": "25 Apr 2025 06:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Stock Surges Almost 1,500%", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOT3hmV2ZCelc2RWVFS2pUbEFIMFdRWmV6UlpVZG5zdC1BN1NObGd0LV9uRFNNZzFLSU9odF9iNklhUTAxbl9LcHRiU1RVWEtWSG5XNWR2ZzVjZ0RodVdrd0FXQ3VzM1FaOTdWRzlLNVVIa1poeFNBVExSRGYwX0UyTmN1Ulh1UjlkVGpfaFJ3ZWdzbkhUYmgxeg?oc=5", "source_name": "entrepreneur.com", "published_at": "2024-10-16T07:00:00+00:00", "published_display": "16 Oct 2024 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $DRUG", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9NbDh3SURFdUNuNlhOMlhnNzlkTGNjWjQ5bU80eVBkcTZlMDByMXR4RUR4cWFGZHFYT1Z5UkxobHJ1LXlnZDk1ei1EOUNueGc1eWViaUp2bVNRUQ?oc=5", "source_name": "MarketBeat", "published_at": "2021-11-18T11:07:25+00:00", "published_display": "18 Nov 2021 11:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPSmoyaHNISzlsNkl4WGxvRGJWd25LSUlROHdkaXZYenpDZHdRTXdPOHk5bC1IbjdLam5rRDR1c05xZ01KcFFOTmhBczRGM1NnbHg4V0VXTmd5QkRNZV9UblpHNXJCeXBaVnRQVnpnRzdlaXJ2cXQxcXgzUUQ5UUp2YzBlRlE1QWJRY1JqYTF4NVA0TU9KQ2RXa2xRWnpGYUJzYmtsRXAwSWh3bnhsSlNnMU92b2VaX1ZkSFpReVJCTm9RQkZHR0lHTWhCam1FbDdTeVlSVFVTMHA1Z3dr?oc=5", "source_name": "GlobeNewswire", "published_at": "2021-03-17T07:00:00+00:00", "published_display": "17 Mar 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 45, "sentiment_summary": {"positive": 15, "negative": 3, "neutral": 27, "score": 57, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.0, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 77.84, "latest_week": "2026-07-10", "one_week_move": 15.1, "four_week_move": 27.7, "twelve_week_move": -13.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.664182, "market_dynamics_buy_signal": false, "relative_strength": -0.689694, "fair_value_gap": 142.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 43.8624, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+15.1% over one week, +27.7% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Traders Daily", "count": 5}, {"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "MarketBeat", "count": 2}, {"label": "Intellectia AI", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+15.1% over one week, +27.7% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5% - Should You Buy?"}], "updated_at": "2026-07-18T00:32:25.608484+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}